Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Liabilities (2018 - 2025)

10x Genomics' Other Non-Current Liabilities history spans 8 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 28.67% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $6.5 million, up 28.67%, while the annual FY2025 figure was $6.5 million, 28.67% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $6.5 million at 10x Genomics, up from $6.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $10.1 million in Q3 2023 and bottomed at $3.0 million in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $6.4 million (2025), against an average of $6.6 million.
  • The largest annual shift saw Other Non-Current Liabilities soared 473.85% in 2021 before it crashed 63.88% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $8.2 million in 2021, then crashed by 63.88% to $3.0 million in 2022, then soared by 43.65% to $4.3 million in 2023, then grew by 17.64% to $5.0 million in 2024, then rose by 28.67% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Non-Current Liabilities are $6.5 million (Q4 2025), $6.4 million (Q3 2025), and $6.1 million (Q2 2025).